Hepatic Toxicity Articles & Analysis
3 articles found
Li et al constructed a novel siRNA delivery system sTOLP(loaded with siRNAOA-R8 / TF-modified LNP) for cell penetrating peptioyl-octadecarginine (OA-R8) transferrin (Tf)-modified multifunctional lipid nanoparticles (LNP). siRNA encapsulated in sTOLP showed strong tumor inhibition (61.7%) and was preferentially absorbed by hepatocytes and tumor cells in HepG2-containing mice without inducing ...
Experiments revealed that the siRNA encapsulated in the sTOLP delivery system showed strong tumor inhibition (61.7%) and can be preferentially absorbed by hepatocytes and tumor cells in HepG2-containing mice without inducing immunogenicity or hepatic or renal toxicity, which brings promise to tumor-specific therapies. 2. ...
The proportion of patients who experienced adverse events attributable to study medication was 65%, 24% and 5%. Immunoxel attenuated hepatic toxicity in patients receiving ART as determined by liver function test. ...